Indication:

  • Treatment of uncomplicated malaria caused by Plasmodium falciparum, including multidrug-resistant strains.
  • Used as part of Artemisinin-based Combination Therapy (ACT).

Dosage (typical 3-day regimen):

Adults and children ≥35 kg:

  • One tablet OD*3/7

Pediatric dose (<35 kg):

  • Dose is weight-based. Follow national malaria treatment guidelines or physician’s instructions
  • Arterolane maleate: Equivalent to 150 mg of arterolane base
  • Piperaquine phosphate: Equivalent to 750 mg of piperaquine base
  • (Note: Pediatric tablets may be lower in strength)
  • Take once daily for 3 consecutive days
  • Take with water and preferably after food to improve absorption
  • Do not skip doses; complete the full treatment course
  • Avoid taking with other medications that affect heart rhythm

Arterolane:

  • A synthetic trioxolane with fast parasite-killing action (similar to artemisinin)
  • Produces reactive oxygen species that damage parasite proteins
  • Rapid reduction of parasitemia

Piperaquine:

  • A long-acting antimalarial from the 4-aminoquinoline group
  • Inhibits heme detoxification, leading to parasite death
  • Maintains therapeutic levels after arterolane is cleared to prevent recurrence

Combination effect:

  • Arterolane clears parasites quickly
  • Piperaquine provides post-treatment prophylaxis and prevents recrudescence

Common:

  • Headache
  • Dizziness
  • Nausea, vomiting
  • Abdominal pain
  • Weakness (asthenia)

Serious (rare):

  • QT interval prolongation (risk of cardiac arrhythmias)
  • Allergic reactions
  • Hepatotoxicity
  • Known hypersensitivity to arterolane or piperaquine
  • Congenital QT prolongation or history of cardiac arrhythmia
  • Severe hepatic or renal impairment
  • Concurrent use of QT-prolonging medications
  • QT-prolonging drugs (e.g., macrolides, quinolones, antipsychotics): May increase risk of cardiac arrhythmias.
  • CYP3A4 inhibitors/inducers: May alter piperaquine levels.
  • Antimalarial drugs or other hepatotoxic agents: Increased risk of adverse effects.

                                   Drug Status

Availability
Pregnancy
Breastfeeding
Schedule
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Synriam TM 150mg/750mg Tablet 3’s Sun Pharma Sun Pharma